


Gilead Sciences' Commitment to the COVID-19 Pandemic

Lee E, Osinusi A, Chokkalingam A, Brainard D, Tran T, Thrun M, Dau L, Wang C, Juneja K
Gilead Sciences, Inc.


Expanding Global Access to Effective Treatment

- Production time optimized from 12 → 6 months
- Gilead donated entire supply of 1.5 M doses of RDV through June
- RDV approved or authorized for temporary use to treat COVID-19 in > 50 countries
- Meeting global demand of RDV supply to treat and stockpile for future spike in COVID-19 cases



Increased supply > 50-fold since Jan 2020 and by 2021 there will be several million treatment courses

Research & Data Generation



Clinical Trials & Data
6 Gilead Sponsored
11 Collaborative
15 Abstracts submitted
4 Publications

COMMIT™ Request for Proposal research grant program with >310 global submissions from 36 countries



Response to the global COVID-19 pandemic

Through multiple cross functional teams, Gilead supports governments, organizations, HCPs, patients to accelerate research, access to remdesivir (RDV), and collaborative education

> 10,000 patients have received RDV through clinical trials

Resources

Patient Support

Gilead COVID-19 Patient Disease Education infographic

Support of independent medical education programs and downloadable patient material



Online Resources:

Remdesivir.com, Gilead.com, AskGileadMedical.com

HCP Support



> 60 Medical Information Global Response documents

> 19 new educational Medical Affairs Slide decks on RDV and COVID-19 internal and HCP use

Medscape and Clinical Care Options COVID-19 resources

Webinars, Microlearning updates, Slide sets, FAQs

> 21,000 Responses to Med Info Inquiries from HCPs and patients

Global Community Support

Philanthropic funds to support nonprofit org. Gilead CARES donations:

- \$20M to nonprofit orgs. impacted by COVID-19
- \$10M to healthcare systems and institutions to address the impact on the frontlines

Gilead matches employee donations to global relief funds to support COVID-19 efforts led by 3 premier orgs.



Gilead and Satcher Health Leadership Institute at Morehouse School of Medicine partnership to address COVID-19 disparities



EUA, Emergency Use Authorization; EU, European Union; NDA, New Drug Application; EAP, Expanded Access Program; SoC, Standard of Care; RW, Real World; DHHS, Department of Human & Health Services

- References:
- Langreth, R. All Eyes on Gilead. Bloomberg BusinessWeek. 14 May 2020
 - Gilead Sciences Update On The Company's Ongoing Response To COVID-19.; 2020. Available at: <https://www.gilead.com/purpose/advancing-global-health/covid-19>
 - An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences.; 2020. Available at: <https://stories.gilead.com/articles/an-open-letter-from-our-chairman-and-ceo-oct-8>
 - Frequently Asked Questions on Remdesivir Pricing and Global Supply.; 2020. Available at: <https://www.gilead.com/-/media/gilead-corporate/files/pdfs/covid-19/gilead-faq-remdesivir-pricing-final.pdf?la=en&hash=52132206BA6D59A29AAC853CE85FE27B>
 - Ongoing Support for Community Organizations.; 2020. Available at: <https://www.gilead.com/purpose/advancing-global-health/covid-19/ongoing-support-for-community-organizations>
 - Gilead Sciences and Satcher Health Leadership Institute at Morehouse School of Medicine Partner to Study Racial Health Inequities Associated with COVID-19.; 2020. Available at: <https://www.gilead.com/news-and-pres/press-room/press-releases/2020/7/gilead-sciences-and-satcher-health-leadership-institute-at-morehouse-school-of-medicine-partner-to-study-racial-health-inequities-associated-with-covid-19>
 - Gilead Data on File

Special Thanks: Becker M (Medical Education & Program); Desai P (Clinical Operation); Dinh T (Med Info); McKeel R (Public Affairs); Ngo D (Graphics); Nguyen K (Project Management- Virology); Sandhu S (Med Info); Zuka K (Corporate Giving)